The following indications are approved by the American College of Hyperbaric Medicine and are reimbursable through CMS:

• Air or Gas Embolism
• Acute Carbon Monoxide Intoxication (Cyanide poisoning)
• Acute Peripheral Arterial Insufficiency
• Chronic Refractory Osteomyelitis
• Clostridial Myonecrosis (Gas Gangrene)
• Compromised Skin Grafts / Tissue Flaps
• Crush Injuries, Compartment Syndrome and Acute Traumatic Ischemias
• Decompression Illness
• Diabetic Foot Ulcer
• Necrotizing Soft Tissue Infections
• Osteoradionecrosis
• Soft Tissue Radionecrosis

The ACHM supports the treatment of patients with non-approved indications only in a research setting using a protocol that has been approved by an Institutional Review Board. The ACHM supports the continued performance of well-designed clinical trials in these areas, especially those that are prospective, randomized, controlled trials. If sufficient data demonstrates that HBO therapy is associated with a favorable risk-benefit ratio for an indication, which is not currently on the approved list from the Centers for Medicare & Medicaid, the Undersea and Hyperbaric Medical Society or a Commercial Insurance Carrier, the ACHM will endorse the application of hyperbaric therapy for the supported indication. Indications that meet these criteria and are supported by the ACHM as appropriate for hyperbaric oxygen therapy include:

• Acute Thermal Burns
• Acute Central Retinal Artery Occlusion
• Acute Frost Bite
• Actinomycosis (only as an adjunct to conventional therapy when the disease process is refractory to antibiotics and surgical treatment)
• Brown Recluse Spider Bite
• Intracranial Brain Abscess 

The ACHM does not support the treatment of non-approved conditions for financial gain, without investigational treatment protocols. College members who intentionally mislead the patient or family into believing that hyperbaric therapy is an approved indication or is supported by peer reviewed literature will be dismissed from the College.